The Hospital Universitario 12 de Octubre is a public general hospital in the neighborhood of Orcasur, in Madrid, Spain. It is part of the hospital network of the Servicio Madrileño de Salud.

There are 1,256 beds in Hospital Universitario 12 de Octubre; Servicio de Oncologia.

During the past decade, Hospital Universitario 12 de Octubre; Servicio de Oncologia conducted 55 clinical trials. In the 10-year time frame, 55 clinical trials started and 32 clinical trials were completed, i.e. on average, 58.2% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 18 clinical trials were completed. i.e. 94.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario 12 de Octubre; Servicio de Oncologia" #1 sponsor was "Hoffmann-La Roche" with 58 trials, followed by "Genentech, Inc." with 5 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 4 trials sponsored, "NovoCure Ltd." with 2 trials sponsored and "BerGenBio ASA" with 2 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario 12 de Octubre; Servicio de Oncologia" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator, "Breast International Group" with 3 trials as a collaborator, "Genentech, Inc." with 2 trials as a collaborator, "SOLTI Breast Cancer Research Group" with 2 trials as a collaborator and "ADIR, a Servier Group company" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario 12 de Octubre; Servicio de Oncologia" are "Breast Cancer" (9 trials), "Bladder Cancer" (4 trials), "Colorectal Cancer" (4 trials), "Non-Small Cell Lung Cancer" (4 trials) and "Ovarian Cancer" (4 trials). Many other conditions were trialed in "Hospital Universitario 12 de Octubre; Servicio de Oncologia" in a lesser frequency.

Most popular intervention types in "Hospital Universitario 12 de Octubre; Servicio de Oncologia" are "Drug" (73 trials), "Other" (4 trials), "Radiation" (4 trials), "Biological" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (29 trials), "Placebo" (18 trials), "Paclitaxel" (13 trials), "Bevacizumab" (10 trials) and "Carboplatin" (9 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario 12 de Octubre; Servicio de Oncologia" are 64 trials for "All" genders, 7 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are NaN active trials in "Hospital Universitario 12 de Octubre; Servicio de Oncologia". undefined are not yet recruiting, 9 are recruiting, 18 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 45 completed trials in Hospital Universitario 12 de Octubre; Servicio de Oncologia, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario 12 de Octubre; Servicio de Oncologia, 11 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".